Labcorp has agreed to acquire Myriad Genetics' prenatal health testing business for over $210 million in cash, expanding its diagnostics portfolio. This deal follows Labcorp's recent acquisition of selected BioReference Health assets, including patient service centers and the 4Kscore Test, for $722 million plus potential earnouts. The acquisitions strengthen Labcorp's position in health diagnostics, with the BioReference assets expected to generate $250 million in revenue in the first year. Myriad's shares rose over 20% in premarket trading following the announcement.
Labcorp's acquisition of Myriad Genetics' prenatal business is the subject, with Pluang market data providing context as of Oct 21, 2026 05:11 WIB. For readers following major cryptocurrencies, 44 of 50 priced assets rose today. Notable movers include VET (VeChain) at Rp129 with a 7.09% increase and a typical hold time of 148 days, MANA (Decentraland) at Rp1.583 up 5.67%, and COTI at Rp202 rising 5.32%.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
